Coleman CI, et al. - Researchers evaluated the efficacy and safety of rivaroxaban vs warfarin in patients with non-valvular atrial fibrillation and diabetes treated in routine practice using US MarketScan claims data for the period November 2011 to December 2016. In contrast with warfarin, rivaroxaban seemed linked to nonsignificant reductions in stroke or systemic embolism and ischemic stroke. Thus, it was supported that rivaroxaban was at least as effective and safe as warfarin in people with diabetes and non-valvular atrial fibrillation treated in routine clinical practice.